Rabbit SARS CoV-2 IgG S1
HEK293 Cells.
Description
Recombinant Anti Rabbit SARS CoV-2 IgG Kappa Spike S1 is a recombinant monoclonal antibody derived from HEK293 cells which recognizes the SARS-CoV and SARS-CoV-2 Spike glycoprotein. CoV-2 IgG S1 Rabbit Antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity at amino acids 318-510 (RBD, Receptor Binding Domain) in the S1 subunit of the Spike protein. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format.
Product Specs
Suitable applications include Enzyme-Linked Immunosorbent Assay (ELISA).
For optimal storage, the product should be kept at 4°C, where it remains stable for up to 2 weeks. For long-term storage, a temperature of -20°C is recommended.
HEK293 Cells.
Protein A affinity purified.
The native monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV
Product Science Overview
The Recombinant Anti-Rabbit SARS-CoV-2 IgG Spike S1 antibody is a significant tool in the fight against the COVID-19 pandemic. This antibody targets the Spike Glycoprotein S1 of the SARS-CoV-2 virus, which is responsible for the virus’s ability to infect host cells. The development and application of this antibody have provided researchers with a powerful means to study the virus and develop potential treatments and vaccines.
The Recombinant Anti-Rabbit SARS-CoV-2 IgG Spike S1 antibody is produced using recombinant DNA technology. This method involves inserting the gene encoding the antibody into a host cell, such as a bacterial or mammalian cell, which then produces the antibody. This approach allows for the production of large quantities of the antibody with high purity and consistency.
The original monoclonal antibody, known as CR3022, was generated by sequencing peripheral blood lymphocytes from a patient exposed to the SARS-CoV virus. This antibody was shown to neutralize SARS-CoV by blocking the interaction between the virus’s receptor-binding domain (RBD) and the host cell’s ACE2 receptor .
The Recombinant Anti-Rabbit SARS-CoV-2 IgG Spike S1 antibody binds to the amino acids 318-510 in the S1 domain of the SARS-CoV-2 Spike protein . This region is crucial for the virus’s ability to bind to the ACE2 receptor on host cells. The antibody also binds to P462L-substituted S318–510 fragments of the SARS-CoV Spike protein . The binding epitope is only accessible in the “open” conformation of the Spike protein .
This antibody is suitable for various applications, including:
- Enzyme-Linked Immunosorbent Assay (ELISA): Used to detect the presence of SARS-CoV-2 antigens or antibodies in a sample.
- Immunofluorescence: Used to visualize the presence of the virus in infected cells.
- Western Blot: Used to detect the presence of SARS-CoV-2 proteins in a sample.
The Recombinant Anti-Rabbit SARS-CoV-2 IgG Spike S1 antibody has been cited in numerous publications and has become a valuable tool in COVID-19 research . It has been used to study the virus’s structure, understand its mechanism of infection, and develop potential treatments and vaccines. The antibody’s ability to bind to a conserved epitope between SARS-CoV and SARS-CoV-2 makes it a versatile tool for studying both viruses .
